Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPM1B | O75688 | 2/20 | 0.56 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.56 |
| ▸ | PPP1CC | P36873 | 2/20 | 0.56 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL765159 | 1.00 | PPM1B (0.56) | PPM1BPTPN1PPP1CCMAPTALDH1A1 | |
| SCHEMBL4269577 | 1.00 | PPM1B (0.56) | PPM1BPTPN1PPP1CCMAPTALDH1A1 | |
| SCHEMBL2318955 | 1.00 | PPM1B (0.56) | PPM1BPTPN1PPP1CCMAPTALDH1A1 | |
| SCHEMBL4269581 | 1.00 | PPM1B (0.56) | PPM1BPTPN1PPP1CCMAPTALDH1A1 | |
| SCHEMBL28222895 | 0.94 | PPM1B (0.58) | PPM1BPTPN1PPP1CCMAPTALDH1A1 | |
| SCHEMBL34475916 | 0.91 | PPM1B (0.66) | PPM1BPTPN1PPP1CCMAPTALDH1A1 | |
| SCHEMBL31162293 | 0.89 | PPM1B (0.53) | PPM1BPTPN1PPP1CCMAPTALDH1A1 | |
| SCHEMBL30546033 | 0.89 | PPM1B (0.53) | PPM1BPTPN1PPP1CCMAPTALDH1A1 | |
| SCHEMBL5116555 | 0.89 | PPM1B (0.53) | PPM1BPTPN1PPP1CCMAPTALDH1A1 | |
| SCHEMBL12632423 | 0.89 | PPM1B (0.53) | PPM1BPTPN1PPP1CCMAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100099660-A1 | METHOD FOR TREATING THROMBOSIS OR EMBOLISM AND RELATED DISEASES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2010-04-22 | — | — | US | disclosed |
| EP-1577301-A1 | DIAMINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2005-09-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100099660-A1 | METHOD FOR TREATING THROMBOSIS OR EMBOLISM AND RELATED DISEASES | F2, PLAT, MPL | PPM1B 2781/4885PTPN1 4621/4885PPP1CC 4471/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.